Upregulation of long noncoding RNA HOXA11 antisense promotes tumor progression and stemness maintenance of cervical cancer cells

Prognostic and clinicopathological significance of long noncoding RNA HOXA11-AS expression in human solid tumors: a meta-analysis

“…Using Cox multivariate analysis in three studies from Kim et al [ 14 , 17 ], Sun et al [ 31 ], and Wang et al [ 26 ], we found that elevated HOXA11-AS expression level was an independent prognostic factor of OS for cancer patients (pooled HR = 1.184, 95% CI 1.050–1.335, p = 0.006), without significant heterogeneity among studies ( p = 0.07; I 2 = 62.4%).…”

“…Li et al [ 35 ] showed that LncRNA HOTAIR enhanced invasion and metastasis of breast cancer. Moreover, lncRNA HOXA11-AS has been found to induce tumor progression and stemness maintenance in cervical cancer [ 14 ]. Many lncRNAs are identified in various types of cancers, and their dysregulated expression is correlated with tumor progression and patients’ survival, thus making them promising markers for the diagnosis and prognosis.…”

“…Mechanisms underlying the regulatory role of HOXA11-AS in tumorigenesis and tumor progression have been extensively investigated in various types of cancer. Kim et al found that HOXA11-AS promoted cancer stem cells (CSCs) self-renewal and EMT in cervical cancer cells through regulating the expression of SOX2, Oct-4, Nanog, E-cadherin, β-catenin, and Vimentin [ 14 ]. Sun et al [ 31 ] revealed that HOXA11-AS served as a critical effector in gastric cancer tumorigenesis and progression via HOXA11-AS/miR-1297/EZH2 crosstalk.…”

“…Protein coding genes are located on the sense strand of the HOXA gene clusters, while noncoding genes are located on the antisense strand [ 13 ]. The lncRNA HOXA11-AS was first identified in cervical cancer [ 14 ], and upregulated HOXA11-AS expression was closely associated with tumor progression and poor prognosis. Then the role of HOXA11-AS in cancer progression was identified in many other types of cancers, including gastric cancer [ 15 ], epithelial ovarian cancers [ 12 ], bladder cancer, cervical cancer [ 14 ] and glioma [ 16 ].…”

“…The lncRNA HOXA11-AS was first identified in cervical cancer [ 14 ], and upregulated HOXA11-AS expression was closely associated with tumor progression and poor prognosis. Then the role of HOXA11-AS in cancer progression was identified in many other types of cancers, including gastric cancer [ 15 ], epithelial ovarian cancers [ 12 ], bladder cancer, cervical cancer [ 14 ] and glioma [ 16 ]. In vitro and in vivo assays evaluating the effects of HOXA11-AS alterations revealed a complex integrated phenotype affecting cell growth, apoptosis, migration, invasion and stemness maintenance through multiple biologic processes, such as epithelial–mesenchymal transition (EMT) [ 13 , 17 ].…”